ReviewMolecular biology reports2025
Role of Mesenchymal Markers in Colorectal Cancer Metastasis.
Review in Molecular biology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Neuron-tumor interplay in colorectal cancer: from mechanisms of onset and progression to targeted therapies.Cell communication and signaling : CCS · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Colorectal cancer (CRC) is the second most common cancer type that results in significant mortality, the primary cause of which is associated with metastasis. Epithelial-mesenchymal transition (EMT) is a biological process that converts polarized epithelial cells into migratory mesenchymal states, which is positively correlated with the dissemination of the tumor cells from the primary tumor site and is thus linked to metastasis. Mesenchymal markers are the proteins that are up-regulated upon initiation of EMT. This review aims to provide a comprehensive overview of the role of mesenchymal markers in CRC metastasis. Upon thorough data mining, fibronectin, vimentin, N-cadherin, and β-catenin were defined as the distinguished mesenchymal markers that are well-studied in the context of CRC metastasis. Expression of these markers was positively correlated with aggressive CRC stages. However, the underlying molecular mechanisms through which they facilitate CRC progression are partly explored. Fibronectin was reported to affect cell migration and invasion via NF-kB/p53 and ITGA5/FAK-P/RhoGTPase axis, while its Extra Domain A (EDA) regulates the lymphangiogenesis via VEGF-C/PI3K/AKT axis. For vimentin and N-cadherin, few upstream regulators have been reported; however, the downstream pathways via which they affect migration and invasion remain to be explored. β-catenin, a well explored molecule for CRC onset, has limited reports in relation to metastatic progression. Wnt/β-catenin signalling has been reported to promote migration and invasion in primary CRC, while it impedes the same in advanced CRC background. There are future scopes for mechanistic research on the underexplored mesenchymal markers, whereas the mechanistically explored molecules need to be tested clinically.
Indexed as
Identifiers
40613936What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.